Recent advances in molecular and cell biology of testicular germ-cell tumors

International Review of Cell and Molecular Biology

Volumn 312, Issue , 2014, Pages 79-100

  Chieffi, Paolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aurora B; GPR30; HMGA; PATZ1; Seminomas; Testicular germ cell tumors

Indexed keywords

ALPHA FETOPROTEIN; ANGIOGENESIS INHIBITOR; AURORA B KINASE; AURORA KINASE INHIBITOR; BARASERTIB; CHORIONIC GONADOTROPIN; ESTROGEN; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; GSK 1070916; HESPERADIN; HIGH MOBILITY GROUP A1A PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; IMATINIB; MESSENGER RNA; MICRORNA; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; NEK2 PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; PROTEIN TYROSINE KINASE INHIBITOR; TOZASERTIB; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX17; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER; UNCLASSIFIED DRUG; VANDETANIB; TUMOR PROTEIN;

ARTICLE; CANCER CYTODIAGNOSIS; CANCER INCIDENCE; CANCER RISK; DISEASE PREDISPOSITION; EMBRYO DEVELOPMENT; EMBRYONAL CARCINOMA; ENVIRONMENTAL FACTOR; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR BIOLOGY; SEMINOMA; TERATOMA; ADULT; CANCER STEM CELL; CELL TRANSFORMATION; CLASSIFICATION; METABOLISM; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; TESTICULAR NEOPLASMS;

ADULT; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASTIC STEM CELLS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84913592754     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800178-3.00003-8     Document Type: Chapter

References (88)

1. Almstrup K., Hoei-Hansen C.E., Wirkner U., Blake J., Schwager C., Ansorge W., et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res. 2004, 64:4736-4743.
2. Atlasi Y., Mowla S.J., Ziaee S.A., Gokhale P.J., Andrews P.W. OCT4 spliced variants are differentially expressed in human pluripotent and non-pluripotent cells. Stem Cells 2008, 26:3068-3074.
3. Avilion A.A., Nicolis S.K., Pevny L.H., Perez L., Vivian N., Lovell Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003, 17:126-140.
4. Barbagallo F., Paronetto M.P., Franco R., Chieffi P., Dolci S., Fry A.M., et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J. Pathol. 2009, 217:431-441.
5. Bernstein E., Kim S.Y., Carmell M.A., Murchison E.P., Alcorn H., Li M.Z., et al. Dicer is essential for mouse development. Nat. Genet. 2003, 35:215-217.
6. Berthelsen J.G., Skakkebaek N.E., von der Maase H., Sorensen B.L., Mogensen P. Screening for carcinoma in situ of the contralateral testis in patients with germinal testicular cancer. Br. Med. J. 1982, 285:1683-1686.
7. Bonner M.R., McCann S.E., Moysich K.B. Dietary factors and the risk of testicular cancer. Nutr. Cancer 2002, 44:35-43.
8. Cao D., Allan R.W., Cheng L., Peng Y., Guo C.C., Dahiya N., et al. RNA-binding protein LIN28 is a marker for testicular germ cell tumors. Hum. Pathol. 2011, 42:710-718.
9. Carmena M., Earnshaw W.C. The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. 2003, 4:842-854.
10. Chaganti R.S., Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res. 2000, 60:1474-1482.
11. Chen Y.T., Chiu R., Lee P., Beneck D., Jin B., Old L.J. Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. Hum. Reprod. 2011, 26:3232-3243.
12. Chen Y.T., Cao D., Chiu R., Lee P. Chromosome X-encoded cancer/testis antigens are less frequently expressed in non-seminomatous germ cell tumors than in seminomas. Cancer Immun. 2013, 13:1-10.
13. Chieffi P. Molecular targets for the treatment of testicular germ cell tumors. Mini Rev. Med. Chem. 2007, 7:755-759.
14. Chieffi P., Chieffi S. Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumours: an overview. J. Cell. Physiol. 2013, 228:1641-1646.
15. Chieffi P., Chieffi S. An up-date on the molecular biomarkers as potential therapeutic targets in human testicular germ cell tumours. Open Androl. J. 2013, 5:6-9.
16. Chieffi P., Chieffi S. An up-date on newly discovered immunohistochemical biomarkers for the diagnosis of human testicular germ cell tumors. Histol. Histopathol 2014, 29:999-1006.
17. Chieffi P., Colucci D'Amato G.L., Staibano S., Franco R., Tramontano D. Estradiol-induced mitogen-activated protein kinase (extracellular signal-regulated kinase 1 and 2) activity in the frog (Rana esculenta) testis. J. Endocrinol. 2000, 167:77-84.
18. Chieffi P., Battista S., Barchi M., Di Agostino S., Pierantoni G., Fedele M., Chiariotti L., Tramontano D., Fusco A. HMGA1 and HMGA2 protein expression in mouse spermatogenesis. Oncogene 2002, 21:3644-3650.
19. Chieffi P., Colucci-D'Amato G.L., Guarino F., Salvatore G., Angelini F. 17β-estradiol induces spermatogonial proliferation through mitogen-activated protein kinase (extracellular signal-regulated kinase 1) activity In the lizard (Podarcis s. sicula). Mol. Reprod. Dev. 2002, 61:218-225.
20. Chieffi P., Troncone G., Caleo A., Libertini S., Linardopoulos S., Tramontano D., Portella G. Aurora B expression in normal testis and seminomas. J. Endocrinol. 2004, 181:263-270.
21. Chieffi P., Franco R., Portella G. Molecular and cell biology of testicular germ cell tumors. Int. Rev. Cell Mol. Biol. 2009, 278:277-308.
22. Chieffi P., Chieffi S., Franco R., Sinisi A. Recent advances in the biology of germ cell tumors: implications for the diagnosis and treatment. J. Endocrinol. Invest. 2012, 35:1015-1020.
23. de Jong J., Looijenga L.H. Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: history and future. Crit. Rev. Oncog. 2006, 12:171-203.
24. de Jong J., Stoop H., Gillis A.J., van Gurp R.J., van de Geijn G.J., Boer M., et al. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. J. Pathol. 2008, 215:21-30.
25. Di Agostino S., Fedele M., Chieffi P., Fusco A., Rossi P., Geremia R., et al. Phosphorylation of high mobility group protein A2 by Nek kinase during the first meiotic division in mouse spermatocytes. Mol. Biol. Cell 2004, 15:1224-1232.
26. Dieckmann K.P., Pichlmeier U. Is risk of testicular cancer related to body size?. Eur. Urol. 2002, 42:564-569.
27. Dieckmann K.P., Endsin G., Pichlmeier U. How valid is the prenatal estrogen excess hypothesis of testicular germ cell cancer? A case control study on hormone-related factors. Eur. Urol. 2001, 40:677-683.
28. Dieckmann K.P., Hartmann J.T., Classen J., Diederichs M., Pichlmeier U. Is increased body mass index associated with the incidence of testicular germ cell cancer?. J. Cancer Res. Clin. Oncol. 2009, 135:731-738.
29. Di Vizio D., Cito L., Boccia A., Chieffi P., Insabato L., Pettinato G., et al. Loss of tumour suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene 2005, 24:1882-1894.
30. Esposito F., Libertini S., Franco R., Abagnale A., Marra L., Portella G., et al. Aurora B expression in post-puberal testicular germ cell tumours. J. Cell. Physiol. 2009, 221:435-439.
31. Esposito F., Boscia F., Franco R., Tornincasa M., Fusco A., Kitazawa S., et al. Down-regulation of estrogen receptor-β associates with transcriptional coregulator PATZ1 delocalization in human testicular seminomas. J. Pathol. 2011, 224:110-120.
32. Esposito F., Boscia F., Gigantino V., Tornincasa M., Fusco A., Franco R., et al. The high mobility group A1-oestrogen receptor β nuclear interaction is impaired in human testicular seminomas. J. Cell. Physiol. 2012, 227:3749-3755.
33. Fedele M., Franco R., Salvatore G., Paronetto M.P., Barbagallo F., Pero R., et al. PATZ1 gene has a critical role in the spermatogenesis and testicular tumours. J. Pathol. 2008, 215:39-47.
34. Ferranti F., Muciaccia B., Ricci G., Dovere L., Canipari R., Magliocca F., et al. Glial cell line-derived neurotrophic factor promotes invasive behaviour in testicular seminoma cells. Int. J. Androl. 2012, 35:758-768.
35. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
36. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur. J. Cancer 1996, 32:2534-2539.
37. Forman D., Oliver R.T., Brett A.R., Marsh S.G., Moses J.H., Bodmer J.G., et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br. J. Cancer 1992, 65:255-262.
38. Franco R., Esposito F., Fedele M., Liguori G., Pierantoni G., Botti G., et al. Detection of high mobility group proteins A1 and A2 represents a valid diagnostic marker in post-puberal testicular germ cell tumours. J. Pathol. 2008, 214:58-64.
39. Franco R., Boscia F., Gigantino V., Marra L., Esposito F., Ferrara D., et al. GPR30 is over-expressed in post puberal testicular germ cell tumors. Cancer Biol. Ther. 2011, 11:609-613.
40. Garner M., Turner M.C., Ghadirian P., Krewski D., Wade M. Testicular cancer and hormonally active agents. J. Toxicol. Environ. Health B Crit. Rev. 2008, 11:260-275.
41. Gasparini G., Longo R., Toi M., Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2005, 2:562-577.
42. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 2004, 10:262-267.
43. Hart A.H., Hartley L., Parker K., Ibrahim M., Looijenga L.H., Pauchnik M., et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 2005, 104:2092-2098.
44. Hauf S., Cole R.W., LaTerra S., Zimmer C., Schnapp G., Walter L., et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 2003, 161:281-294.
45. Heinrich M.C., Blanke C.D., Druker B.J., Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 2002, 20:1692-1703.
46. Hoei-Hansen C.E., Almstrup K., Nielsen J.E., Brask Sonne S., Graem N., Skakkebaek N.E., et al. Stem cell pluripotency factor NANOG is expressed inhuman fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology 2005, 47:48-56.
47. Jones R.H., Vasey P.A. Part II: testicular cancer-management of advanced disease. Lancet Oncol. 2003, 4:738-747.
48. Kedde M., Strasser M.J., Boldajipour B., Oude Vrielink J.A., Slanchev K., le Sage C., et al. RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell 2007, 131:1273-1286.
49. Keen N., Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 2004, 4:927-936.
50. Kemmer K., Corless C.L., Fletcher J.A., McGreevey L., Haley A., Griffith D., et al. KIT mutations are common in testicular seminomas. Am. J. Pathol. 2004, 164:305-313.
51. Kim I., Saunders T.L., Morrison S.J. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell 2007, 130:470-483.
52. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353:172-187.
53. Ledford H. Doubts raised over stem-cell marker. Nature 2007, 449:647.
54. Lee D. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin. Lung Cancer 2005, 7:89-91.
55. Linger R., Dudakia D., Huddart R., Tucker K., Friedlander M., Phillips K.A., et al. Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes Cancer 2008, 47:247-252.
56. Looijenga L.H., de Leeuw H., van Oorschot M., van Gurp R.J., Stoop H., Gillis A.J., et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res. 2003, 63:7674-7678.
57. Loveland K.L., Schlatt S. Stem cell factor and c-kit in the mammalian testis: lessons originating from Mother Nature's gene knockouts. J. Endocrinol. 1997, 153:337-344.
58. Lutke Holzik M.F., Rapley E.A., Hoekstra H.J., Sleijfer D.T., Nolte I.M., Sijmons R.H. Genetic predisposition to testicular germ-cell tumours. Lancet Oncol. 2004, 5:363-371.
59. Maatouk D.M., Loveland K.L., McManus M.T., Moore K., Harfe B.D. Dicer1 is required for differentiation of the mouse male germline. Biol. Reprod. 2008, 79:696-703.
60. Manova K., Nocka K., Besmer P., Bachvarova R.F. Gonadal expression of c-kit encoded at the W locus of the mouse. Development 1990, 110:1057-1069.
61. Martin O.V., Shialis T., Lester J.N., Scrimshaw M.D., Boobis A.R., Voulvoulis N. Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative metaanalysis. Environ. Health Perspect. 2008, 116:149-157.
62. McCoshen J.A., McCallion D.J. A study of the primordial germ cells during their migratory phase in Steel mutant mice. Experientia 1975, 31:589-590.
63. McGlynn K.A., Quraishi S.M., Graubard B.I., Weber J.P., Rubertone M.V., Erickson R.L. Persistent organochlorine pesticides and risk of testicular germ cell tumors. J. Natl. Cancer Inst. 2008, 100:663-671.
64. Meng X., de Rooij D.G., Westerdahl K., Saarma M., Sariola H. Promotion of seminomatous tumors by targeted overexpression of glial cell line-derived neurotrophic factor in mouse testis. Cancer Res. 2001, 61:3267-3271.
65. Muller J., Skakkebaek N.E., Nielsen O.H., Graem N. Cryptorchidism and testis cancer. A typical infantile germ cells followed by carcinoma in situ and invasive carcinoma in adulthood. Cancer 1984, 54:629-634.
66. Naro C., Barbagallo F., Chieffi P., Bourgeois C., Paronetto M.P., Sette C. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival. Nucleic Acids Res. 2014, 42:3218-3227.
67. Nielsen H., Nielsen M., Skakkebaek N.E. The fine structure of possible carcinoma in-situ in the seminiferous tubules in the testis of four infertile men. Acta Pathol. Microbiol. Scand. A 1974, 82:235-248.
68. Oosterhuis J.W., Looijenga L.H. Testicular germ-cell tumors in a broader perspective. Nat. Rev. Cancer 2005, 5:210-222.
69. Ota T., Suto S., Katayama H., Han Z.B., Suzuki F., Maeda M., et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 2002, 62:5168-5177.
70. Palumbo C., van Roozendaal K., Gillis A.J., van Gurp R.H., de Munnik H., Oosterhuis J.W., et al. Expression of the PDGF alpha-receptor 1.5kb transcript, OCT-4, and c-KIT in human normal and malignant tissues Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms. J. Pathol. 2002, 196:467-477.
71. Pero R., Lembo F., Di Vizio D., Boccia A., Chieffi P., Fedele M., et al. RNF4 is a growth inhibitor expressed in germ cells and lost in human testicular tumours. Am. J. Pathol. 2001, 159:1225-1230.
72. Pero R., Lembo F., Chieffi P., Del Pozzo G., Fedele M., Fusco A., et al. Translational regulation of a novel testis-specific RNF4 transcript. Mol. Reprod. Dev. 2003, 66:1-7.
73. Portella G., Passaro C., Chieffi P. Aurora B: a new prognostic marker and therapeutic target in cancer. Curr. Med. Chem. 2011, 18:482-496.
74. Rajpert-De Meyts E., Skakkebaek N.E. Pathogenesis of testicular carcinoma in situ and germ cell cancer: still more questions than answers. Int. J. Androl. 2011, 34:e2-e6.
75. Ranieri G., Patruno R., Ruggirei E., Montemurro S., Valerio P., Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem. 2006, 1:1845-1847.
76. Skakkebaek N.E. Possible carcinoma-in-situ of the testis. Lancet 1972, 2:2516-2517.
77. Skakkebaek N.E., Berthelsen J.G., Giwercman A., Muller J. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int. J. Androl. 1987, 10:19-28.
78. Sorrentino V., Giorgi M., Geremia R., Besmer P., Rossi P. Expression of the c-kit proto-oncogene in the murine male germ cells. Oncogene 1991, 6:149-151.
79. Staibano S., Ilardi G., Leone V., Luise C., Merolla F., Esposito F., et al. Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors. BMC Cancer 2013, 13:433.
80. Strohsnitter W.C., Noller K.L., Hoover R.N., Robboy S.J., Palmer J.R., Titus-Ernstoff L., et al. Cancer risk in men exposed in utero to diethylstilbestrol. J. Natl. Cancer Inst. 2001, 93:545-551.
81. Terada Y., Tatsuka M., Suzuki F., Yasuda Y., Fujita S., Otsu M.A. AIM-1: a mammalian midbody-associated protein required forcytokinesis. EMBO J. 1998, 17:667-676.
82. Ulbright T.M. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod. Pathol. 2005, 18:S61-S79.
83. Vicini E., Loiarro M., Di Agostino S., Corallini S., Capolunghi F., Carsetti R., et al. 17-β-estradiol elicits genomic and non-genomic responses in mouse male germ cells. J. Cell. Physiol. 2006, 206:238-245.
84. von Eyben F.E. Laboratory markers and germ cell tumors. Crit. Rev. Clin. Lab. Sci. 2003, 40:377-427.
85. Voorhoeve P.M., le Sage C., Schrier M., Gillis A.J., Stoop H., Nagel R., et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006, 124:1169-1181.
86. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006, 66:1883-1890.
87. Yamaguchi S., Kimura H., Tada M., Nakatsuji N., Tada T. Nanog expression in mouse germ cell development. Gene Expr. Patterns 2005, 5:639-646.
88. Zakarija A., Soff G. Update on angiogenesis inhibitors. Curr. Opin. Oncol. 2005, 6:578-583.